Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test could spot Crohn's and colitis earlier

NCT ID NCT03833310

Diagnosis Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at four substances in the blood (Osteoprotegerin, sRANKL, NFkB, and TFF3) to see if they could help diagnose inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. Researchers measured these markers in 70 newly diagnosed patients before and after treatment. The goal is to find a noninvasive, accurate way to diagnose IBD without relying solely on endoscopy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood test measuring Osteoprotegerin, sRANKL, NFkB, and TFF3
What this could lead to
If successful, these blood markers could help doctors diagnose Crohn's disease and ulcerative colitis more accurately and less invasively.
What could go wrong
This is a small, completed study with only 70 participants. The markers may not prove accurate enough for routine use, and results need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

70 people

The number who actually took part.

Started

Nov 2019

Finished

Apr 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

After standardized work-up with clinical, endoscopic, histopathologicial and, when applicable, radiological evaluation, all patients will met the generally accepted international diagnostic criteria of inflamatory bowel diseaes .The healthy controls consisted of an age- and gender-matched (negative for IBD). This group did not show evidence or familial history of IBD or any other immune mediated disorders

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Newly diagnosed patients (untreated) by clinical and endoscopic examination and not received treatment . Exclusion Criteria: * patients have autoimmune diseases * patients with cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Crohn disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inflammatory bowel diseases

Contacts and locations

Locations

  • Assuit Medical University

    Asyut, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.